Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports

Artificial Intelligence in Medicine

Volumn 76, Issue , 2017, Pages 7-15

  Cai, Ruichu ^a   Liu, Mei ^b   Hu, Yong ^c   Melton, Brittany L ^d   Matheny, Michael E ^e,f   Xu, Hua ^g   Duan, Lian ^h   Waitman, Lemuel R ^b  

^a GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c JINAN UNIVERSITY   (China)

^d UNIVERSITY OF KANSAS   (United States)

^e Veterans Administration   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h HOFSTRA UNIVERSITY   (United States)

Author keywords

Adverse drug reaction; Association rule; Causality; Drug drug interaction

Indexed keywords

ASSOCIATION REACTIONS; ASSOCIATION RULES; BAYESIAN NETWORKS; DRUG PRODUCTS; PHARMACODYNAMICS;

ADVERSE DRUG REACTIONS; ASSOCIATION RULE DISCOVERY; CAUSAL RELATIONSHIPS; CAUSALITY; DRUG-DRUG INTERACTIONS; FOOD AND DRUG ADMINISTRATION'S; HEALTH CARE PROFESSIONALS; REPORTING SYSTEMS;

DRUG INTERACTIONS;

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMIODARONE; ANALGESIC AGENT; CARBOPLATIN; CELECOXIB; CILOSTAZOL; DEXAMETHASONE; DOCETAXEL; ESOMEPRAZOLE; GLYCERYL TRINITRATE; ISOTRETINOIN; METFORMIN; PARACETAMOL; PEMETREXED; POTASSIUM; PREDNISONE; RAMIPRIL; RANITIDINE; ROSIGLITAZONE; SIMVASTATIN; WARFARIN;

ADVERSE DRUG REACTION; ARTICLE; CORONARY ARTERY DISEASE; DRUG DOSE REDUCTION; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FALSE POSITIVE RESULT; FEMUR FRACTURE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INTESTINAL BLEEDING; PHARMACIST; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; TAXONOMY; BAYES THEOREM; DATA MINING; DRUG SURVEILLANCE PROGRAM; MACHINE LEARNING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BAYES THEOREM; DATA MINING; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MACHINE LEARNING;

EID: 85013192692     PISSN: 09333657     EISSN: 18732860     Source Type: Journal    
DOI: 10.1016/j.artmed.2017.01.004     Document Type: Article

References (55)

1. [1] Health, United States 2014: with Special Feature on Adults Aged 55–64. 2015, National Center for Health Statistics, Hyattsville, MD.
2. [2] Lazarou, J., Pomeranz, B.H., Corey, P.N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998), 1200–1205.
3. [3] Johnson, J.A., Bootman, J.L., Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 155 (1995), 1949–1956.
4. [4] Pirmohamed, M., Drug interactions of clinical importance. 1998, Chapman & Hall.
5. [5] Khwaja, A., KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120 (2012), c179–c184.
6. [6] Duke, J.D., Li, X., Dexter, P., Adherence to drug-drug interaction alerts in high-risk patients: a trial of context-enhanced alerting. J Am Med Inform Assoc 20 (2013), 494–498.
7. [7] Banda, J.M., Callahan, A., Winnenburg, R., Strasberg, H.R., CamiBen, A., Reis, Y., et al. Feasibility of prioritizing drug–drug-event associations found in electronic health records. Drug Saf 39:1 (2016), 45–57.
8. [8] Goldman, J.L., Sullins, A., Sandritter, S., Leeder, J.S., Lowry, J., Pediatric pharmacovigilance enhancing adverse drug reaction reporting in a tertiary care children's hospital. Ther Innov Regul Sci 47 (2013), 566–571.
9. [9] Bate, A., Evans, S.J., Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18 (2009), 427–436.
10. [10] de Abajo, F.J., Montero, D., Madurga, M., Garcia Rodriguez, L.A., Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 58 (2004), 71–80.
11. [11] Almenoff, J.S., DuMouchel, W., Kindman, L.A., Yang, X., Fram, D., Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 12 (2003), 517–521.
12. [12] Puijenbroek, E., Bate, A., Leufkens, H.G.M., Lindquist, M., Orre, R., Egberts, A.C.G., et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11 (2002), 3–10.
13. [13] Szarfman, A., Machado, S.G., O'Neill, R.T., Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 25 (2002), 381–392.
14. [14] Bate, A., Lindquist, M., Edwards, I.R., Olsson, S., Orre, R., Lansner, A., Freitas, R.M., et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54 (1998), 315–321.
15. [15] Hauben, M., Madigan, D., Gerrits, C.M., Walsh, L., Van Puijenbroek, E.P., The role of data mining in pharmacovigilance. Expert Opin Drug Saf 4 (2005), 929–948.
16. [16] Almenoff, J., Tonning, J.M., Gould, A.L., Szarfman, A., Hauben, M., Ouellet-Hellstrom, R., et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 28 (2005), 981–1007.
17. [17] Almenoff, J.S., Pattishall, E.N., Gibbs, T.G., DuMouchel, W., Evans, S., Yuen, N., Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 82 (2007), 157–166.
18. [18] Ahmed, I., Thiessard, F., Miremont-Salame, G., Begaud, B., Tubert-Bitter, P., Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study. Clin Pharmacol Ther 88 (2010), 492–498.
19. [19] Van Puijenbroek, E.P., Egberts, A.C., Meyboom, R.H., Leufkens, H.G., Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol 47 (1999), 689–693.
20. [20] Thakrar, B.T., Grundschober, S.B., Doessegger, L., Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 64 (2007), 489–495.
21. [21] van Puijenbroek, E.P., Egberts, A.C., Heerdink, E.R., Leufkens, H.G., Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 56 (2000), 733–738.
22. [22] Tatonetti, N., Denny, J., Murphy, S., Fernald, G., Krishnan, G., Castro, V., et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 90 (2011), 133–142.
23. [23] Tatonetti, N.P., Fernald, G.H., Altman, R.B., A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc 19 (2012), 79–85.
24. [24] Harpaz, R., Chase, H.S., Friedman, C., Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics, 11(Suppl. 9), 2010, S7.
25. [25] Harpaz, R., Perez, H., Chase, H.S., Rabadan, R., Hripcsak, G., Friedman, C., Biclustering of adverse drug events in the FDA's spontaneous reporting system. Clin Pharmacol Ther 89 (2011), 243–250.
26. [26] Pearl, J., Causality: models, reasoning and inference. first edition, 2000, Cambridge Univ Press.
27. [27] Schulz, K.F., Chalmers, I., Hayes, R.J., Altman, D.G., Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995), 408–412.
28. [28] Rothman, K.J., Causes. Am J Epidemiol 141 (1976), 90–95 discussion 89 (1995).
29. [29] Dekkers, O.M., von Elm, E., Algra, A., Romijn, J.A., Vandenbroucke, J.P., How to assess the external validity of therapeutic trials: a conceptual approach. Int J Epidemiol 39 (2010), 89–94.
30. [30] Heckerman, D., Geiger, D., Chickering, D.M., Learning Bayesian networks: the combination of knowledge and statistical data. Mach Learn 20 (1995), 197–243.
31. [31] Hoyer, P.O., Janzing, D., Mooij, J., Peters, M., Scholkopf, B., Nonlinear causal discovery with additive noise models. 2008, Neural Information Processing Systems (NIPS), 689–696.
32. [32] Zhang, K., Hyvärinen, A., On the identifiability of the post-nonlinear causal model. UAI 64 (2009), 7–655.
33. [33] Pearl, J., From Bayesian network to causal networks. Bayesian Netw Probab Reason, 1994, 1–31.
34. [34] Chickering, D.M., Heckerman, D., Meek, C., Large-sample learning of Bayesian networks is NP-hard. J Mach Learn Res 5 (2004), 1287–1330.
35. [35] Cooper, G.F., A simple contraint-based algorithm for efficiently mining observational databases for causal relationships. Data Min Knowl Discov 1 (1997), 203–224.
36. [36] Pellet, J.P., Using Markov blankets for causal structure learning. J Mach Learn Res 9 (2008), 1295–1342.
37. [37] Aliferis, C.F., Statnikov, A., Tsannardinos, I., Mani, S., Koutsoukos, X.D., Local causal and Markov blanket induction for causal discovery and feature selection for classification Part I: algorithms and empirical evaluation. J Mach Learn Res 11 (2010), 171–234.
38. [38] Cai, R., Zhang, Z., Hao, Z., Causal gene identification using combinatorial V-structure search. Neural Netw 43 (2013), 63–71.
39. [39] Cai, R., Zhang, Z., Hao, Z., SADA: a general framework to support robust causation discovery. ICML 20 (2013), 8–216.
40. [40] Ji, Y., Ying, H., Dews, P., Mansour, A., Tran, J., Miller, R.E., et al. A potential causal association mining algorithm for screening adverse drug reactions in postmarketing surveillance. IEEE Trans Inf Technol Biomed 15 (2011), 428–437.
41. [41] J. Li, et al., in IEEE 13th International Conference on Data Mining Workshops (ICDMW) 114–23 (Dallas, TX, 2013).
42. [42] Xu, H., Stenner, S.P., Doan, S., Johnson, K.B., Waitman, L.R., Denny, J.C., MedEx: a medication information extraction system for clinical narratives. J Am Med Inform Assoc 17 (2010), 19–24.
43. [43] Welcome to MedDRA and the MSSO, .
44. [44] Noren, G.N., Orre, R., Bate, A., Edwards, I.R., Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov 14 (2007), 305–328, 10.1007/s10618-006-0052-8.
45. [45] Reich, L., ‘Extreme duplication’ in the USFDA adverse events reporting system database. Drug Saf 30 (2007), 551–554.
46. [46] Jin, H., Chen, J., He, H., Williams, G.J., Kelman, C., et al. Mining unexpected temporal associations: applications in detecting adverse drug reactions. IEEE Trans Inf Technol Biomed 48 (2008), 8–500.
47. [47] Vinh, N.X., Epps, J., Bailey, J., Information theoretic measures for clusterings comparison: variants, properties, normalization and correction for chance. J Mach Learn Res 11 (2010), 2837–2854.
48. [48] KDIGO, KDIGO clinical practice guideline for acute kidney injury. Kidney Int(Suppl. 2), 2012, 1–141.
49. [49] Epocrates, .
50. [50] UpToDate, .
51. [51] Hou, S.H., Bushinsky, D.A., Wish, J.B., Cohen, J.J., Harrington, J.T., Hospital-acquired renal insufficiency: a prospective study. Am J Med 74 (1983), 243–248.
52. [52] McCullough, P.A., Adam, A., Becker, C.R., Davidson, C., Lameire, N., Stacul, F., Risk prediction of contrast-induced nephropathy. Am J Cardiol 98 (2006), 27K–36K, 10.1016/j.amjcard.2006.01.022.
53. [53] Spirtes, P., Glymour, C., Scheines, R., Cusation, prediction, and search. second edition, 2001.
54. [54] Hoyer, P.O., Janzing, D., Mooij, J., Peters, M., Scholkopf, B., Nonlinear causal discovery with additive noise models. 2008, Neural Information Processing Systems (NIPS), Vancouver, Canada, 689–696.
55. [56] Cai, R., Tung, A.K.H., Zhang, Z.J., Hao, Z.F., What is unequal among the equals? Ranking equivalent rules from gene expression data. IEEE Trans Knowl Data Eng 23:11 (2011), 1735–1747.